Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Balance Sheet
9 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 82.00 | 298.00 | 376.00 | 347.00 | 334.00 | 676.00 | 1,294.00 | 1,520.00 | 1,300.00 | |
|
Current
|
77.00 | 281.00 | 354.00 | 324.00 | 289.00 | 597.00 | 769.00 | 1,216.00 | 998.00 | |
| Cash And Equivalents | 75.00 | 273.00 | 340.00 | 58.00 | 57.00 | 160.00 | 123.00 | 523.00 | 226.00 | |
| Assets | 82.00 | 298.00 | 376.00 | 347.00 | 334.00 | 676.00 | 1,294.00 | 1,520.00 | 1,300.00 | |
| Accounts Receivables (AR) | - - | -5.00 | -4.00 | 2.00 | 2.00 | 2.00 | - - | -1.00 | -32.00 | |
| Inventory | - - | - - | - - | - - | - - | -19.00 | -337.00 | -69.00 | - - | |
| Short Term Investments | - - | - - | - - | 255.00 | 222.00 | 437.00 | 625.00 | 669.00 | 685.00 | |
| Other Current Assets | - - | 1.00 | 3.00 | 3.00 | 5.00 | 17.00 | 18.00 | 20.00 | 49.00 | |
|
Non Current
|
4.00 | 17.00 | 21.00 | 22.00 | 44.00 | 78.00 | 525.00 | 303.00 | 302.00 | |
| Property, Plant, Equipment (Net) | 2.00 | 10.00 | 15.00 | 17.00 | 37.00 | 55.00 | 100.00 | 160.00 | 148.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | 4.00 | 1.00 | 425.00 | 142.00 | 154.00 | |
| Other Non Current Assets | 1.00 | 7.00 | 6.00 | 5.00 | 2.00 | 21.00 | - - | - - | - - | |
| Liabilities | 14.00 | 89.00 | 75.00 | 69.00 | 64.00 | 149.00 | 254.00 | 284.00 | 250.00 | |
|
Current
|
10.00 | 30.00 | 31.00 | 40.00 | 35.00 | 64.00 | 125.00 | 126.00 | 115.00 | |
| Accounts Payable | - - | 1.00 | - - | - - | 1.00 | 5.00 | - - | -4.00 | 2.00 | |
| Short Term Debt | - - | - - | - - | - - | 5.00 | 5.00 | 9.00 | 16.00 | 18.00 | |
| Deferred Revenue | 6.00 | 20.00 | 21.00 | 27.00 | 12.00 | 22.00 | 63.00 | 43.00 | 22.00 | |
| Tax Payable | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 2.00 | 5.00 | 7.00 | 10.00 | 13.00 | 25.00 | 43.00 | 60.00 | 67.00 | |
|
Non Current
|
4.00 | 58.00 | 44.00 | 28.00 | 28.00 | 84.00 | 128.00 | 157.00 | 135.00 | |
| Long Term Debt | - - | - - | - - | - - | 12.00 | 33.00 | 64.00 | 114.00 | 96.00 | |
| Leasing Obligations | - - | - - | - - | - - | 18.00 | 39.00 | 74.00 | 130.00 | 115.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | -16.00 | -51.00 | -63.00 | - - | -38.00 | |
| Other Non Current Liabilities | - - | - - | - - | - - | 16.00 | 51.00 | 63.00 | 24.00 | 38.00 | |
| Equity | 67.00 | 209.00 | 300.00 | 277.00 | 269.00 | 527.00 | 1,040.00 | 1,235.00 | 1,050.00 | |
| Stockholders' Equity | 67.00 | 209.00 | 300.00 | 277.00 | 269.00 | 527.00 | 1,040.00 | 1,235.00 | 1,050.00 | |
| Retained Earnings | -21.00 | -53.00 | -121.00 | -201.00 | -300.00 | -435.00 | -703.00 | -1,177.00 | -1,658.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Profit | -12.00 | -31.00 | -67.00 | -85.00 | -92.00 | -125.00 | -259.00 | -490.00 | -481.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | 89.00 | 263.00 | 421.00 | 478.00 | 570.00 | 962.00 | 1,745.00 | 2,420.00 | 2,710.00 | |
| Loss Other Compr. Income | - - | - - | - - | - - | - - | - - | -2.00 | -7.00 | -2.00 |